Abstract: Disclosed are anti-PD-1 antibodies and use of an anti-PD-1 antibody in a combination therapy. Treatment methods are disclosed and include administering to a patient in need an effective amount of an anti-PD-1 antibody and a therapeutic agent. Methods for treating a tumor or cancer using anti-PD-1 antibody and a therapeutic agent are disclosed.

Abstract: CD47 antibodies and use thereof are disclosed, particularly to monoclonal antibodies that recognize CD47, and more particularly to CD47 antibodies that do not cause significant levels of hemagglutination, red blood cell reduction and platelet reduction, and to a method for preparing these antibodies and use of these monoclonal antibodies in the manufacture of medicaments for treating cancer or infection.

Abstract: The present invention provides an anti-HER2 antibody and use thereof, wherein the antibody provided by the present invention can be used for the treatment of HER2-positive diseases, and can also be used for the diagnosis and prognosis of HER2-positive diseases. The Antibody BAT0303F disclosed herein is expressed by a host cell with fucosyltransferase knocked out, and can enhance ADCC effect of the antibody.

Abstract: A dispatching method for an electric-hydrogen energy system considering flexible hydrogen demand includes establishing an electric load flexibility equation, a power purchase and sale constraint equation, a renewable energy output constraint equation, a hydrogen load flexibility equation, an electricity-to-hydrogen production safety operation constraint equation and an electric power balance constraint equation, establishing an electric-hydrogen energy system dispatching model with the lowest operating cost of the electric-hydrogen energy system within the dispatching cycle as an objective function, and solving the electric-hydrogen energy system dispatching model to obtain an optimal dispatching result. As compared with the prior art, the present invention can effectively solve the problem of coordination between electric and hydrogen energy flows, while taking into account the flexibility of electric and hydrogen loads, further providing additional flexibility to the operation of the system.

Abstract: The present invention generally relates to compounds comprising antibodies, antigen-binding fragments thereof, polypeptides, and immunoconjugates that bind to TROP2 (TACSTD2). The present invention also relates to methods of using such TROP2-binding molecules for diagnosing and treating diseases, such as malignancies.

Abstract: The present invention generally relates to compounds comprising antibodies, antigen-binding fragments thereof, polypeptides, and immunoconjugates that bind to TROP2 (TACSTD2). The present invention also relates to methods of using such TROP2-binding molecules for diagnosing and treating diseases, such as malignancies.

Abstract: Disclosed herein are anti-ERB B2/NEU antibodies conjugated with maytansinoid drugs for targeted delivery to disease tissues. Methods relating to the preparation and uses of such drug conjugates to treat ERB B2/NEU positive cells in cancers are provided.

Abstract: Disclosed herein are anti-ERB B2/NEU antibodies conjugated with maytansinoid drugs for targeted delivery to disease tissues. Methods relating to the preparation and uses of such drug conjugates to treat ERB B2/NEU positive cells in cancers are provided.

Abstract: Disclosed herein are maytansinoid drug linker derivatives which can be linked to a antigen binding unit (Abu), and maytansinoid drugs linked with an antigen binding unit (Drug-Linker-Antigen binding Unit: D-L-Abu), for targeted delivery to disease tissues. D-L-Abu, D-L-Abu derivatives, and methods relating to the use of such drug conjugates to treat antigen positive cells in cancers and immunological disorders are provided.

Abstract: Disclosed herein are maytansinoid drug linker derivatives which can be linked to a antigen binding unit (Abu), and maytansinoid drugs linked with an antigen binding unit (Drug-Linker-Antigen binding Unit: D-L-Abu), for targeted delivery to disease tissues. D-L-Abu, D-L-Abu derivatives, and methods relating to the use of such drug conjugates to treat antigen positive cells in cancers and immunological disorders are provided.

Abstract: Disclosed herein are anti-ERB B2/NEU antibodies conjugated with maytansinoid drugs for targeted delivery to disease tissues. Methods relating to the preparation and uses of such drug conjugates to treat ERB B2/NEU positive cells in cancers are provided.

Abstract: Disclosed herein are maytansinoid drug linker derivatives which can be linked to a antigen binding unit (Abu), and maytansinoid drugs linked with an antigen binding unit (Drug-Linker-Antigen binding Unit: D-L-Abu), for targeted delivery to disease tissues. D-L-Abu, D-L-Abu derivatives, and methods relating to the use of such drug conjugates to treat antigen positive cells in cancers and immunological disorders are provided.

Abstract: Disclosed herein are maytansinoid drug linker derivatives which can be linked to a antigen binding unit (Abu), and maytansinoid drugs linked with an antigen binding unit (Drug-Linker-Antigen binding Unit: D-L-Abu), for targeted delivery to disease tissues. D-L-Abu, D-L-Abu derivatives, and methods relating to the use of such drug conjugates to treat antigen positive cells in cancers and immunological disorders are provided.

Abstract: A martensitic stainless steel alloy is strengthened by copper-nucleated nitride precipitates. The alloy includes, in combination by weight percent, about 10.0 to about 12.5 Cr, about 2.0 to about 7.5 Ni, up to about 17.0 Co, about 0.6 to about 1.5 Mo, about 0.5 to about 2.3 Cu, up to about 0.6 Mn, up to about 0.4 Si, about 0.05 to about 0.15 V, up to about 0.10 N, up to about 0.035 C, up to about 0.01 W, and the balance Fe and incidental elements and impurities. The nitride precipitates may be enriched by one or more transition metals.

Abstract: Disclosed herein are maytansinoid drug linker derivatives which can be linked to a antigen binding unit (Abu), and maytansinoid drugs linked with an antigen binding unit (Drug-Linker-Antigen binding Unit: D-L-Abu), for targeted delivery to disease tissues. D-L-Abu, D-L-Abu derivatives, and methods relating to the use of such drug conjugates to treat antigen positive cells in cancers and immunological disorders are provided.

Abstract: Aluminum alloys having improved strength at 300° C. characterized by formation from an intermediate amorphous state to a final fcc matrix hardened by optimal 25 nm-diameter Ll2 precipitates with an interphase misfit less than about 4% in all three dimensions and Al23Ni6M4 precipitates where M is one or more elements selected from the group consisting of Y and Yb. An appropriate melt of aluminum with selected transition metals (Co, Cu, Fe, Ni, Ti, Y) and Ll2 stabilizers (Sc, Yb) in amounts of about 2 to 12 and 2 to 15 atomic percent, respectively, is processed to achieve an intermediate amorphous state to dissolve Ll2-forming components. The amorphous alloys are then thermo-mechanically devitrified to a final crystalline microstructure. The alloys have good ductility and a short-term tensile strength exceeding about 275 MPa (40 ksi) at 300° C., and are useful for applications such as high-temperature turbine engine components or aircraft structural components.

Abstract: Aluminum alloys having improved strength characteristics at elevated temperatures (300° C.) are manufactured by combining selected transition metals (Ni, Co, Ti, Fe, Y, Sc) and selected rare earth materials (Er, Tm, Tb, Lu) in amounts of about 2 to 12% and 2 to 15% atomic percent respectively in an amorphous, glassy state and subsequently devitrifying the amorphous material to form a crystalline mix of fcc and L12 phase material. Devitrification from the amorphous state may be effected by various means including thermal and thermo mechanical processes.